Apremilast Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Apremilast comprises 226 peer-reviewed publications across 15 journals, 24 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Psoriasis, COVID-19, Dermatomyositis, and Lichen Planus. Most recent publication: Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial., J Eur Acad Dermatol Venereol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
    Wilsmann-Theis D, Kromer C, Gerdes S, et al. · J Eur Acad Dermatol Venereol · 2021
    PubMed: PMID 34077577 · NCT04572997 (APLANTUS) · Psoriasis
  2. Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.
    Strand V, Schett G, Hu C, et al. · J Rheumatol · 2014
    PubMed: PMID 23588944 · NCT00456092 · Arthritis, Psoriatic
  3. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.
    Reich K, Mrowietz U, Menter A, et al. · J Eur Acad Dermatol Venereol · 2021
    PubMed: PMID 34255891 · NCT01194219 (ESTEEM 1)
  4. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
    Pathan E, Abraham S, Van Rossen E, et al. · Ann Rheum Dis · 2013
    PubMed: PMID 22984171 · NCT00944658 (START) · Spondylitis, Ankylosing
  5. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
    Paller AS, Hong Y, Becker EM, et al. · J Am Acad Dermatol · 2020
    PubMed: PMID 31408686 · NCT02576678 · Psoriasis
  6. Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.
    Khemis A, Fontas E, Moulin S, et al. · J Invest Dermatol · 2021
    PubMed: PMID 32004567 · NCT03036995 (Rapid Vitiligo) · Vitiligo
  7. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. · J Rheumatol · 2016
    PubMed: PMID 25593233 · NCT01172938 (PALACE-1) · Psoriasis
  8. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ, Blanco FJ, Crowley J, et al. · Ann Rheum Dis · 2017
    PubMed: PMID 26792812 · NCT01212770 (PALACE 3) · Psoriasis

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01172938
PALACE-1
PsoriasisPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
Baseline and Week 16
Apremilast 20 mg30.4 percentage of participants
Apremilast 30 mg38.1 percentage of participants
Placebo19.0 percentage of participants
NCT01194219
ESTEEM 1
—Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline
Baseline to Week 16
Placebo (PBO)5.3 percentage of participants
Placebo/Apremilast33.1 percentage of participants
NCT01212757
PALACE2
PsoriasisPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
Baseline and Week 16
Apremilast 20 mg37.4 percentage of participants
Apremilast 30 mg32.1 percentage of participants
Placebo18.9 percentage of participants
NCT01212770
PALACE 3
PsoriasisPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
Baseline and Week 16
Apremilast 20 mg28.4 percentage of participants
Apremilast 30 mg40.7 percentage of participants
Placebo18.3 percentage of participants
NCT01232283
ESTEEM 2
—Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline
Baseline to Week 16
Apremilast28.8 percentage of participants
Placebo5.8 percentage of participants
NCT01307423
PALACE4
PsoriasisPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
Baseline and Week 16
Apremilast 20mg28.0 percentage of participants
Apremilast 30mg30.7 percentage of participants
Placebo15.9 percentage of participants
NCT01583374
POSTURE
Spondylitis, AnkylosingPercentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16
Baseline and Week 16
Apremilast 20 mg35.0 Percentage of Participants
Apremilast 30 mg32.5 Percentage of Participants
Placebo36.6 Percentage of Participants
NCT01690299PsoriasisPercentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline
Baseline to Week 16
Apremilast Plus Placebo Injection39.8 Percentage of participants
Placebo11.9 Percentage of participants
NCT01925768Arthritis, PsoriaticPercentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 16
Baseline and Week 16
Apremilast (APR) 30 mg38.2 percentage of participants
Placebo (PBO)20.2 percentage of participants
NCT02307513Behcet SyndromeArea Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12)
Oral ulcers were assessed at weeks 0 (baseline), 1, 2, 4, 6, 8, 10, and 12 during the placebo-controlled period.
Apremilast 30 mg BID129.54 Ulcers*days (±15.943 Standard Error)
Placebo222.14 Ulcers*days (±15.886 Standard Error)
NCT03123471
STYLE
PsoriasisPercentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline
Baseline to Week 16
Apremilast43.3 Percentage of Participants
Placebo/Apremilast13.7 Percentage of Participants
NCT03611751
POETYK-PSO-2
PsoriasisThe Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)
Baseline and Week 16
BMS-986165271 Participants
Placebo24 Participants
NCT03611751
POETYK-PSO-2
PsoriasisThe Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)
Week 16
BMS-986165253 Participants
Placebo22 Participants
NCT03624127
POETYK-PSO-1
PsoriasisThe Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)
Baseline and Week 16
BMS-986165194 Participants
Placebo21 Participants
NCT03624127
POETYK-PSO-1
PsoriasisThe Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)
Week 16
BMS-986165178 Participants
Placebo12 Participants
NCT03701763PsoriasisPercentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16
Baseline to Week 16
Apremilast33.1 percentage of participants
Placebo11.5 percentage of participants
NCT03721172
ADVANCE
PsoriasisPercentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase
Baseline and Week 16 of the placebo-controlled phase
Placebo-controlled Phase: Apremilast 30 mg21.6 Percentage of participants
Placebo-controlled Phase: Placebo4.1 Percentage of participants
NCT03777436
DISCREET
PsoriasisPercentage of Participants With a Modified sPGA-G Response at Week 16
Baseline and Week 16 of the Placebo-controlled Phase
Placebo-controlled Phase: Apremilast 30 mg39.6 Percentage of participants
Placebo-controlled Phase: Placebo19.5 Percentage of participants
NCT03930186—Percentage of Participants Who Achieved an sPGA Score of Clear (0) or Almost Clear (1) at Week 16
Week 16
Apremilast43.7 percentage of participants
NCT04590586
COMMUNITY
COVID-19Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29
Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
Apremilast + Standard of Care14.0 days
Apremilast Placebo Control14.0 days
NCT04590586
COMMUNITY
COVID-19Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29
Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
Lanadelumab + Standard of Care10.0 days
Lanadelumab Placebo Control15.5 days
NCT04590586
COMMUNITY
COVID-19Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29
Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
Zilucoplan + Standard of Care14.0 days
Zilucoplan Placebo Control15.0 days
NCT04908189Arthritis, PsoriaticNumber of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16
Week 16
Deucravacitinib169 Participants
Placebo123 Participants
NCT05174065PsoriasisPercentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at Week 16
Baseline and Week 16
Placebo-controlled Period: Apremilast67.8 percentage of participants
Placebo-controlled Period: Placebo35.3 percentage of participants

Publications by year

1966–2026: 226 publications.

1966
1
1978
1
1992
2
1993
1
1994
1
1997
2
1998
1
1999
1
2001
2
2002
3
2003
2
2004
3
2005
4
2006
6
2007
3
2008
8
2009
8
2010
8
2011
9
2012
9
2013
17
2014
6
2015
7
2016
6
2017
9
2018
9
2019
7
2020
10
2021
14
2022
18
2023
18
2024
10
2025
13
2026
7

Publications by indication

Psoriasis (73)

  • Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.
    J Eur Acad Dermatol Venereol · 2026 · PMID 41297955 · NCT05174065
  • Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.
    J Eur Acad Dermatol Venereol · 2026 · PMID 41369155 · NCT03777436
  • Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis.
    Dermatol Ther (Heidelb) · 2026 · PMID 41350512 · NCT03611751
  • Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.
    Dermatol Ther (Heidelb) · 2025 · PMID 41060491 · NCT07169682
  • Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials.
    J Dermatol · 2025 · PMID 40066907 · NCT03624127

COVID-19 (23)

  • Phosphatidylethanol measures in patients with severe COVID-19-associated respiratory failure identify a subset with alcohol misuse.
    Alcohol Clin Exp Res (Hoboken) · 2026 · PMID 39592213 · NCT04488081
  • Anti-CD14 treatment in patients with severe COVID-19: Clinical and biological effects in a Phase 2 randomized open-label adaptive platform clinical trial.
    CHEST Crit Care · 2026 · PMID 40462830 · NCT04488081
  • Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial.
    EClinicalMedicine · 2026 · PMID 36883141 · NCT04488081
  • Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial.
    Intensive Care Med · 2025 · PMID 40261382 · NCT02735707
  • Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial.
    Thorax · 2025 · PMID 40360262 · NCT02735707

Dermatomyositis (16)

  • Apremilast in Recalcitrant Cutaneous Dermatomyositis: A Nonrandomized Controlled Trial.
    JAMA Dermatol · 2022 · PMID 36197661 · NCT03529955
  • The pathogenesis of dermatomyositis.
    Br J Dermatol · 2019 · PMID 28542733 · NCT03529955
  • MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
    Cancer Res · 2018 · PMID 28993409 · NCT03529955
  • Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study.
    Sci Rep · 2018 · PMID 28487565 · NCT03529955
  • Elevated IL-4 and IFN-γ Levels in Muscle Tissue of Patients with Dermatomyositis.
    In Vivo · 2018 · PMID 28652434 · NCT03529955

Lichen Planus (14)

  • Incidence of Oral Lichen Planus in Perimenopausal Women: A Cross-sectional Study in Western Uttar Pradesh Population.
    J Midlife Health · 2022 · PMID 28706407 · NCT06260904
  • Lichen planus - a clinical guide.
    J Dtsch Dermatol Ges · 2021 · PMID 34096678 · NCT06260904
  • Efficacy of ozonized water for the treatment of erosive oral lichen planus: a randomized controlled study.
    Med Oral Patol Oral Cir Bucal · 2020 · PMID 32683383 · NCT06260904
  • A prospective observational study to compare efficacy of topical triamcinolone acetonide 0.1% oral paste, oral methotrexate, and a combination of topical triamcinolone acetonide 0.1% and oral methotrexate in moderate to severe oral lichen planus.
    Dermatol Ther · 2018 · PMID 29124831 · NCT06260904
  • Treatment of erosive oral lichen planus with methotrexate.
    J Dtsch Dermatol Ges · 2016 · PMID 26972194 · NCT06260904

Dermatitis, Atopic (12)

  • A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis.
    J Invest Dermatol · 2020 · PMID 30528828 · NCT02087943
  • A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.
    Arch Dermatol · 2012 · PMID 22508772 · NCT01393158
  • Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights.
    J Allergy Clin Immunol · 2009 · PMID 18992925 · NCT00931242
  • Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
    Int Immunopharmacol · 2009 · PMID 18854230 · NCT00931242
  • What are the best outcome measurements for atopic eczema? A systematic review.
    J Allergy Clin Immunol · 2008 · PMID 17910890 · NCT00931242

Arthritis, Psoriatic (10)

  • Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST.
    Rheumatology (Oxford) · 2026 · PMID 42384964 · NCT03747939
  • Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study.
    Lancet Rheumatol · 2025 · PMID 39488216 · NCT03783026
  • Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice.
    Reumatol Clin (Engl Ed) · 2024 · PMID 38233009 · NCT03828045
  • Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study.
    Rheumatol Ther · 2024 · PMID 38416391 · NCT03608657
  • Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial.
    Ann Rheum Dis · 2024 · PMID 39164067 · NCT03747939

Publications by journal

  • J Eur Acad Dermatol Venereol11 papers
  • Dermatol Ther (Heidelb)11 papers
  • J Am Acad Dermatol10 papers
  • N Engl J Med9 papers
  • Blood8 papers
  • Ann Rheum Dis6 papers
  • JAMA6 papers
  • J Rheumatol5 papers
  • J Invest Dermatol5 papers
  • Br J Dermatol5 papers

Trial-results highlights

In studies evaluating Apremilast for psoriatic arthritis, participants achieved an American College of Rheumatology 20% (ACR20) response at Week 16. In NCT01172938 (PALACE-1), 30.4% of participants in the Apremilast 20 mg arm and 38.1% in the Apremilast 30 mg arm achieved an ACR20 response, compared to 19.0% in the placebo arm. Similarly, in NCT01212757 (PALACE2), 37.4% of participants in the Apremilast 20 mg arm and 32.1% in the Apremilast 30 mg arm achieved this response, versus 18.9% in the placebo arm. For NCT01212770 (PALACE 3), 28.4% of participants in the Apremilast 20 mg arm and 40.7% in the Apremilast 30 mg arm achieved an ACR20 response, while 18.3% in the placebo arm did. In NCT01307423 (PALACE4), 28.0% of participants in the Apremilast 20mg arm and 30.7% in the Apremilast 30mg arm achieved an ACR20 response, compared to 15.9% in the placebo arm.

For psoriasis, studies assessed the percentage of participants who achieved a 75% improvement (PASI-75) in the Psoriasis Area Severity Index at Week 16. In NCT01194219 (ESTEEM 1), 33.1% of participants in the Placebo/Apremilast arm achieved a PASI-75 response, compared to 5.3% in the placebo arm. In NCT01232283 (ESTEEM 2), 28.8% of participants in the Apremilast arm achieved a PASI-75 response, while 5.8% in the placebo arm did. Another study, NCT01690299, reported that 39.8% of participants in the Apremilast Plus Placebo Injection arm achieved a PASI-75 response, versus 11.9% in the placebo arm.

In a study for ankylosing spondylitis, NCT01583374 (POSTURE), the percentage of participants who achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) response at Week 16 was evaluated. In this trial, 35.0% of participants in the Apremilast 20 mg arm and 32.5% in the Apremilast 30 mg arm achieved an ASAS 20 response, compared to 36.6% in the placebo arm. All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Apremilast publications (226)

2026 (7 papers)

  1. Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.
    Terui T, Okubo Y, Kobayashi S, et al. · J Eur Acad Dermatol Venereol · 2026 · Derived
    PubMed: PMID 41297955 · NCT05174065 · Psoriasis
  2. Phosphatidylethanol measures in patients with severe COVID-19-associated respiratory failure identify a subset with alcohol misuse.
    Pomponio R, Peterson RA, Owusu M, et al. · Alcohol Clin Exp Res (Hoboken) · 2026 · Derived
    PubMed: PMID 39592213 · NCT04488081 (I-SPY_COVID) · COVID-19
  3. Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.
    Merola JF, Guenther L, Lynde C, et al. · J Eur Acad Dermatol Venereol · 2026 · Derived
    PubMed: PMID 41369155 · NCT03777436 (DISCREET) · Psoriasis
  4. Anti-CD14 treatment in patients with severe COVID-19: Clinical and biological effects in a Phase 2 randomized open-label adaptive platform clinical trial.
    Mabrey FL, Martin TR, Calfee CS, et al. · CHEST Crit Care · 2026 · Derived
    PubMed: PMID 40462830 · NCT04488081 (I-SPY_COVID) · COVID-19
  5. Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial.
    I-SPY COVID Consortium · EClinicalMedicine · 2026 · Derived
    PubMed: PMID 36883141 · NCT04488081 (I-SPY_COVID) · COVID-19
  6. Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST.
    Coates LC, Gladman DD, Merola JF, et al. · Rheumatology (Oxford) · 2026 · Derived
    PubMed: PMID 42384964 · NCT03747939 (FOREMOST) · Arthritis, Psoriatic
  7. Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis.
    Armstrong AW, Warren RB, Sofen H, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
    PubMed: PMID 41350512 · NCT03611751 (POETYK-PSO-2) · Psoriasis

2025 (13 papers)

  1. Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.
    Tsiogka A, Soulaidopoulos S, Gregoriou S, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 41060491 · NCT07169682 · Psoriasis
  2. Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial.
    REMAP-CAP Investigators, Angus DC · Intensive Care Med · 2025 · Derived
    PubMed: PMID 40261382 · NCT02735707 (REMAP-CAP) · COVID-19
  3. Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials.
    Morita A, Imafuku S, Tada Y, et al. · J Dermatol · 2025 · Derived
    PubMed: PMID 40066907 · NCT03624127 (POETYK-PSO-1) · Psoriasis
  4. Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms.
    Merola JF, Mease PJ, Armstrong AW, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 40445270 · NCT03611751 (POETYK-PSO-2) · Psoriasis
  5. Multicentre phase II open study assessing the efficacy and safety of apremilast in children and adults with epidermolysis bullosa simplex generalised: study protocol for the EBULO study.
    Fontas E, Hubiche T, Maruani A, et al. · BMJ Open · 2025 · Derived
    PubMed: PMID 41224305 · NCT06509984 (EBULO) · Epidermolysis Bullosa Simplex
  6. Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial.
    Derde L, Gordon AC, Mouncey PR, et al. · Thorax · 2025 · Derived
    PubMed: PMID 40360262 · NCT02735707 (REMAP-CAP) · COVID-19
  7. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
    Armstrong AW, Lebwohl M, Warren RB, et al. · JAMA Dermatol · 2025 · Derived
    PubMed: PMID 39602111 · NCT03624127 (POETYK-PSO-1) · Psoriasis
  8. Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials.
    Armstrong AW, Kircik L, Stein Gold L, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 40113724 · NCT03611751 (POETYK-PSO-2) · Psoriasis
  9. Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
    Armstrong AW, Augustin M, Beaumont JL, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 39080153 · NCT03624127 (POETYK-PSO-1) · Psoriasis
  10. Challenges Psoriasis and Its Impact on Quality of Life: Challenges in Treatment and Management.
    Ponikowska M, Vellone E, Czapla M, et al. · Psoriasis (Auckl) · 2025 · Background
    PubMed: PMID 40330837 · NCT07366268 · Psoriasis
  11. Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study.
    Østergaard M, Boesen M, Maksymowych WP, et al. · Lancet Rheumatol · 2025 · Background
    PubMed: PMID 39488216 · NCT03783026 (MOSAIC) · Arthritis, Psoriatic
  12. Psoriasis: an update on topical and systemic therapies.
    Chan JJ · Aust Prescr · 2025 · Background
    PubMed: PMID 40568686 · NCT07366268 · Psoriasis
  13. Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life.
    Augustin M, Barker J, Conrad C, et al. · Dermatol Ther (Heidelb) · 2025 · Background
    PubMed: PMID 40317400 · NCT03774875 (EMBRACE) · Psoriasis

2024 (10 papers)

  1. Simvastatin in Critically Ill Patients with Covid-19.
    REMAP-CAP Investigators, Hills TE, Lorenzi E, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 37888913 · NCT02735707 (REMAP-CAP) · COVID-19
  2. Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1).
    Papp KA, Beyska-Rizova S, Gantcheva ML, et al. · J Eur Acad Dermatol Venereol · 2024 · Derived
    PubMed: PMID 38279575 · NCT03168256
  3. Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice.
    Gratacós-Masmitja J, Beltrán Catalán E, Álvarez Vega JL, et al. · Reumatol Clin (Engl Ed) · 2024 · Derived
    PubMed: PMID 38233009 · NCT03828045 (PREVAIL) · Arthritis, Psoriatic
  4. Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study.
    Chandran V, Bessette L, Thorne C, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 38416391 · NCT03608657 (APPRAISE) · Arthritis, Psoriatic
  5. Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis.
    Armstrong AW, Park SH, Patel V, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 38907877 · NCT03624127 (POETYK-PSO-1) · Psoriasis
  6. Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from PROMINENT.
    Abe M, Okubo Y, Takahashi H, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 38801606 · NCT03930186
  7. Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study.
    Okubo Y, Terui T, Kobayashi S, et al. · Dermatol Ther (Heidelb) · 2024 · Background
    PubMed: PMID 38896381 · NCT04057937 · Psoriasis
  8. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
    Merola JF, Parish LC, Guenther L, et al. · J Am Acad Dermatol · 2024 · Background
    PubMed: PMID 37852306 · NCT03777436 (DISCREET) · Psoriasis
  9. Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial.
    Gossec L, Coates LC, Gladman DD, et al. · Ann Rheum Dis · 2024 · Background
    PubMed: PMID 39164067 · NCT03747939 (FOREMOST) · Arthritis, Psoriatic
  10. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.
    Fiorillo L, Becker E, de Lucas R, et al. · J Am Acad Dermatol · 2024 · Background
    PubMed: PMID 38266683 · NCT03701763 · Psoriasis

2023 (18 papers)

  1. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
    Writing Committee for the REMAP-CAP Investigators, Lawler PR, Derde LPG, et al. · JAMA · 2023 · Derived
    PubMed: PMID 37039790 · NCT02735707 (REMAP-CAP) · COVID-19
  2. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
    Strober B, Thaçi D, Sofen H, et al. · Immunotherapy · 2023 · Derived
    PubMed: PMID 37150956 · NCT03611751 (POETYK-PSO-2) · Psoriasis
  3. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
    Stein Gold LF, Bagel J, Tyring SK, et al. · Br J Dermatol · 2023 · Derived
    PubMed: PMID 37488811 · NCT04908475 · Psoriasis
  4. The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors.
    Nurmi V, Knight C, Estcourt L, et al. · J Infect Dis · 2023 · Derived
    PubMed: PMID 36967714 · NCT02735707 (REMAP-CAP) · COVID-19
  5. Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome.
    Mease PJ, Hatemi G, Paris M, et al. · Am J Clin Dermatol · 2023 · Derived
    PubMed: PMID 37316690 · NCT01925768 · Arthritis, Psoriatic
  6. Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.
    LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators, Adhikari NKJ, Hashmi M, et al. · JAMA · 2023 · Derived
    PubMed: PMID 37877585 · NCT02735707 (REMAP-CAP) · COVID-19
  7. The Needs of Patients with Psoriasis and Benefits of Apremilast in French Clinical Practice: Results from the Observational REALIZE Study.
    Jullien D, Richard MA, Halioua B, et al. · Dermatol Ther (Heidelb) · 2023 · Derived
    PubMed: PMID 37204608 · NCT03757013 (REALIZE) · Psoriasis
  8. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.
    Goligher EC, Lawler PR, Jensen TP, et al. · JAMA · 2023 · Derived
    PubMed: PMID 36942550 · NCT02735707 (REMAP-CAP) · COVID-19
  9. Antiplatelet agents for the treatment of adults with COVID-19.
    Fischer AL, Messer S, Riera R, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37489818 · NCT02735707 (REMAP-CAP) · COVID-19
  10. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary.
    Armstrong AW, Gooderham M, Warren RB, et al. · Immunotherapy · 2023 · Derived
    PubMed: PMID 37150952 · NCT03624127 (POETYK-PSO-1) · Psoriasis
  11. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
    PubMed: PMID 35129472 · NCT07352566 · Psoriasis
  12. Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
    Terui T, Okubo Y, Kobayashi S, et al. · Am J Clin Dermatol · 2023 · Background
    PubMed: PMID 37233897 · NCT04057937 · Psoriasis
  13. Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation.
    Sarango-Granda P, Silva-Abreu M, Calpena AC, et al. · Pharmaceuticals (Basel) · 2023 · Background
    PubMed: PMID 33371334 · NCT07366268 · Psoriasis
  14. Apremilast loaded lyotropic liquid crystalline nanoparticles embedded hydrogel for improved permeation and skin retention: An effective approach for psoriasis treatment.
    Rapalli VK, Tomar Y, Sharma S, et al. · Biomed Pharmacother · 2023 · Background
    PubMed: PMID 37018989 · NCT07366268 · Psoriasis
  15. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
    Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
    PubMed: PMID 37672566 · NCT07352566 · Psoriasis
  16. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
    Mrowietz U, Barker J, Conrad C, et al. · J Eur Acad Dermatol Venereol · 2023 · Background
    PubMed: PMID 36300769 · NCT03774875 (EMBRACE) · Psoriasis
  17. Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study.
    Giofrè C, Fabbrocini G, Potenza C, et al. · Adv Ther · 2023 · Background
    PubMed: PMID 37171752 · NCT04031027 (DARWIN) · Psoriasis
  18. Topical Therapy in Psoriasis.
    Ahmed SS, Manchanda Y, De A, et al. · Indian J Dermatol · 2023 · Background
    PubMed: PMID 37822388 · NCT07366268 · Psoriasis

2022 (18 papers)

  1. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
    Wells AF, Edwards CJ, Kivitz AJ, et al. · Rheumatology (Oxford) · 2022 · Derived
    PubMed: PMID 34100922 · NCT01307423 (PALACE4) · Psoriasis
  2. Non-steroidal anti-inflammatory drugs for acute gout.
    van Durme CM, Wechalekar MD, Landewé RB, et al. · Cochrane Database Syst Rev · 2022 · Derived
    PubMed: PMID 34882311 · NCT00997581 · Gout
  3. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
    REMAP-CAP Writing Committee for the REMAP-CAP Investigators, Bradbury CA, Lawler PR, et al. · JAMA · 2022 · Derived
    PubMed: PMID 35315874 · NCT02735707 (REMAP-CAP) · COVID-19
  4. Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study.
    Okubo Y, Takahashi H, Hino R, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 35689737 · NCT03930186
  5. Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials.
    Mease PJ, Gladman DD, Kavanaugh A, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 34536218 · NCT01172938 (PALACE-1) · Psoriasis
  6. Endothelial glycocalyx and microvascular perfusion are associated with carotid intima-media thickness and impaired myocardial deformation in psoriatic disease.
    Ikonomidis I, Pavlidis G, Lambadiari V, et al. · J Hum Hypertens · 2022 · Derived
    PubMed: PMID 34819613 · NCT02144857 · Psoriasis
  7. Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
    Hatemi G, Mahr A, Takeno M, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 35798511 · NCT02307513 · Behcet Syndrome
  8. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
    Gladman DD, Kavanaugh A, Gómez-Reino JJ, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 30018799 · NCT01212757 (PALACE2) · Psoriasis
  9. Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study.
    Ghislain PD, Lambert J, Lam Hoai XL, et al. · Adv Ther · 2022 · Derived
    PubMed: PMID 34977985 · NCT03097003 (OTELO) · Psoriasis
  10. Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial.
    Gelfand JM, Shin DB, Armstrong AW, et al. · JAMA Dermatol · 2022 · Derived
    PubMed: PMID 36129688 · NCT03082729 (VIP-A) · Psoriasis
  11. Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.
    de Vlam K, Toukap AN, Kaiser MJ, et al. · Adv Ther · 2022 · Derived
    PubMed: PMID 34977986 · NCT03096990 (APOLO) · Arthritis, Psoriatic
  12. Apremilast in Recalcitrant Cutaneous Dermatomyositis: A Nonrandomized Controlled Trial.
    Bitar C, Ninh T, Brag K, et al. · JAMA Dermatol · 2022 · Derived
    PubMed: PMID 36197661 · NCT03529955 · Dermatomyositis
  13. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
    Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
    PubMed: PMID 35788566 · NCT07352566 · Psoriasis
  14. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
    Stein Gold L, Papp K, Pariser D, et al. · J Am Acad Dermatol · 2022 · Background
    PubMed: PMID 34343599 · NCT03721172 (ADVANCE) · Psoriasis
  15. Novel nanocrystal-based formulations of apremilast for improved topical delivery.
    Parmar PK, Bansal AK · Drug Deliv Transl Res · 2022 · Background
    PubMed: PMID 32588281 · NCT07366268 · Psoriasis
  16. Incidence of Oral Lichen Planus in Perimenopausal Women: A Cross-sectional Study in Western Uttar Pradesh Population.
    Mohan RPS, Gupta A, Kamarthi N, et al. · J Midlife Health · 2022 · Background
    PubMed: PMID 28706407 · NCT06260904 · Lichen Planus
  17. Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.
    Mease PJ, Kavanaugh A, Ogdie A, et al. · J Rheumatol · 2022 · Background
    PubMed: PMID 35428720 · NCT01307423 (PALACE4) · Psoriasis
  18. I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations.
    Files DC, Matthay MA, Calfee CS, et al. · BMJ Open · 2022 · Background
    PubMed: PMID 35667714 · NCT04488081 (I-SPY_COVID) · COVID-19

2021 (14 papers)

  1. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
    Wilsmann-Theis D, Kromer C, Gerdes S, et al. · J Eur Acad Dermatol Venereol · 2021 · Trial result
    PubMed: PMID 34077577 · NCT04572997 (APLANTUS) · Psoriasis
  2. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.
    Reich K, Mrowietz U, Menter A, et al. · J Eur Acad Dermatol Venereol · 2021 · Trial result
    PubMed: PMID 34255891 · NCT01194219 (ESTEEM 1)
  3. Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.
    Khemis A, Fontas E, Moulin S, et al. · J Invest Dermatol · 2021 · Trial result
    PubMed: PMID 32004567 · NCT03036995 (Rapid Vitiligo) · Vitiligo
  4. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
    Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF, et al. · JAMA · 2021 · Derived
    PubMed: PMID 34606578 · NCT02735707 (REMAP-CAP) · COVID-19
  5. Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations.
    UPMC REMAP-COVID Group, on behalf of the REMAP-CAP Investigators · Trials · 2021 · Derived
    PubMed: PMID 33509275 · NCT02735707 (REMAP-CAP) · COVID-19
  6. Research Priorities for U.K. Pediatric Critical Care in 2019: Healthcare Professionals' and Parents' Perspectives.
    Tume LN, Menzies JC, Ray S, et al. · Pediatr Crit Care Med · 2021 · Derived
    PubMed: PMID 33394942 · NCT02735707 (REMAP-CAP) · COVID-19
  7. A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis.
    Taylor PC, van der Heijde D, Landewé R, et al. · J Rheumatol · 2021 · Derived
    PubMed: PMID 33589554 · NCT01583374 (POSTURE) · Spondylitis, Ankylosing
  8. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
    REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 33631065 · NCT02735707 (REMAP-CAP) · COVID-19
  9. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
    REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 34351722 · NCT02735707 (REMAP-CAP) · COVID-19
  10. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N, Hirsch C, Chai KL, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34473343 · NCT04488081 (I-SPY_COVID) · COVID-19
  11. Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
    Danese S, Neurath MF, Kopoń A, et al. · Clin Gastroenterol Hepatol · 2021 · Derived
    PubMed: PMID 31926340 · NCT02289417 (UC) · Colitis, Ulcerative
  12. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
    ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 34351721 · NCT02735707 (REMAP-CAP) · COVID-19
  13. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
    Arabi YM, Gordon AC, Derde LPG, et al. · Intensive Care Med · 2021 · Derived
    PubMed: PMID 34251506 · NCT02735707 (REMAP-CAP) · COVID-19
  14. Lichen planus - a clinical guide.
    Solimani F, Forchhammer S, Schloegl A, et al. · J Dtsch Dermatol Ges · 2021 · Background
    PubMed: PMID 34096678 · NCT06260904 · Lichen Planus

2020 (10 papers)

  1. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
    Paller AS, Hong Y, Becker EM, et al. · J Am Acad Dermatol · 2020 · Trial result
    PubMed: PMID 31408686 · NCT02576678 · Psoriasis
  2. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.
    Wells AF, Edwards CJ, Kivitz AJ, et al. · Rheumatology (Oxford) · 2020 · Derived
    PubMed: PMID 29635379 · NCT01307423 (PALACE4) · Psoriasis
  3. A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis.
    Simpson EL, Imafuku S, Poulin Y, et al. · J Invest Dermatol · 2020 · Derived
    PubMed: PMID 30528828 · NCT02087943 · Dermatitis, Atopic
  4. Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations.
    Mease PJ, Gladman DD, Ogdie A, et al. · Arthritis Care Res (Hoboken) · 2020 · Derived
    PubMed: PMID 31909868 · NCT01212770 (PALACE 3) · Psoriasis
  5. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A, Gladman DD, Edwards CJ, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 31077258 · NCT01212770 (PALACE 3) · Psoriasis
  6. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
    Angus DC, Derde L, Al-Beidh F, et al. · JAMA · 2020 · Derived
    PubMed: PMID 32876697 · NCT02735707 (REMAP-CAP) · COVID-19
  7. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.
    Angus DC, Berry S, Lewis RJ, et al. · Ann Am Thorac Soc · 2020 · Derived
    PubMed: PMID 32267771 · NCT02735707 (REMAP-CAP) · COVID-19
  8. Efficacy of ozonized water for the treatment of erosive oral lichen planus: a randomized controlled study.
    Veneri F, Bardellini E, Amadori F, et al. · Med Oral Patol Oral Cir Bucal · 2020 · Background
    PubMed: PMID 32683383 · NCT06260904 · Lichen Planus
  9. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.
    Parisi R, Iskandar IYK, Kontopantelis E, et al. · BMJ · 2020 · Background
    PubMed: PMID 32467098 · NCT07366268 · Psoriasis
  10. Randomized, Investigator-Blinded Study to Compare the Efficacy and Tolerance of a 650-microsecond, 1064-nm YAG Laser to a 308-nm Excimer Laser for the Treatment of Mild to Moderate Psoriasis Vulgaris.
    Nestor MS, Fischer D, Arnold D, et al. · J Drugs Dermatol · 2020 · Background
    PubMed: PMID 32129962 · NCT07366268 · Psoriasis

2019 (7 papers)

  1. Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.
    Wang Y, Coyne K, Sofen H, et al. · J Dermatolog Treat · 2019 · Derived
    PubMed: PMID 30747550 · NCT03123471 (STYLE) · Psoriasis
  2. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
    Hatemi G, Mahr A, Ishigatsubo Y, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31722152 · NCT02307513 · Behcet Syndrome
  3. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ, Pelletier C, Ung B, et al. · J Med Econ · 2019 · Background
    PubMed: PMID 30652520 · NCT00773734 · Psoriasis
  4. The pathogenesis of dermatomyositis.
    Thompson C, Piguet V, Choy E, et al. · Br J Dermatol · 2019 · Background
    PubMed: PMID 28542733 · NCT03529955 · Dermatomyositis
  5. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P, Ohson K, Walsh J, et al. · Ann Rheum Dis · 2019 · Background
    PubMed: PMID 29343507 · NCT01925768 · Arthritis, Psoriatic
  6. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
    Knuckles MLF, Levi E, Soung J, et al. · J Dermatolog Treat · 2019 · Background
    PubMed: PMID 30339049 · NCT00773734 · Psoriasis
  7. Immunologic, microbial, and epithelial interactions in atopic dermatitis.
    Brunner PM, Leung DYM, Guttman-Yassky E, et al. · Ann Allergy Asthma Immunol · 2019 · Background
    PubMed: PMID 29126710 · NCT03741933 (CHD)

2018 (9 papers)

  1. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L, Bagel J, Lebwohl M, et al. · J Drugs Dermatol · 2018 · Derived
    PubMed: PMID 29462231 · NCT02425826 (UNVEIL) · Parapsoriasis
  2. MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
    Saba NS, Wong DH, Tanios G, et al. · Cancer Res · 2018 · Background
    PubMed: PMID 28993409 · NCT03529955 · Dermatomyositis
  3. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M, Okubo Y, Komine M, et al. · J Dermatol · 2018 · Background
    PubMed: PMID 28391657 · NCT01988103 · Psoriasis
  4. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
    Ohtsuki M, Kubo H, Morishima H, et al. · J Dermatol · 2018 · Background
    PubMed: PMID 29905383 · NCT01988103 · Psoriasis
  5. Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study.
    Oda K, Kotani T, Takeuchi T, et al. · Sci Rep · 2018 · Background
    PubMed: PMID 28487565 · NCT03529955 · Dermatomyositis
  6. Defining and treating moderate plaque psoriasis: a dermatologist survey.
    Knuckles MLF, Levi E, Soung J, et al. · J Dermatolog Treat · 2018 · Background
    PubMed: PMID 29502473 · NCT00773734 · Psoriasis
  7. Elevated IL-4 and IFN-γ Levels in Muscle Tissue of Patients with Dermatomyositis.
    Giriş M, Durmuş H, Yetimler B, et al. · In Vivo · 2018 · Background
    PubMed: PMID 28652434 · NCT03529955 · Dermatomyositis
  8. A prospective observational study to compare efficacy of topical triamcinolone acetonide 0.1% oral paste, oral methotrexate, and a combination of topical triamcinolone acetonide 0.1% and oral methotrexate in moderate to severe oral lichen planus.
    Chauhan P, De D, Handa S, et al. · Dermatol Ther · 2018 · Background
    PubMed: PMID 29124831 · NCT06260904 · Lichen Planus
  9. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
    Bissonnette R, Haydey R, Rosoph LA, et al. · J Eur Acad Dermatol Venereol · 2018 · Background
    PubMed: PMID 29055155 · NCT03741933 (CHD)

2017 (9 papers)

  1. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ, Blanco FJ, Crowley J, et al. · Ann Rheum Dis · 2017 · Trial result
    PubMed: PMID 26792812 · NCT01212770 (PALACE 3) · Psoriasis
  2. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K, Gooderham M, Green L, et al. · J Eur Acad Dermatol Venereol · 2017 · Derived
    PubMed: PMID 27768242 · NCT01690299 · Psoriasis
  3. Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis.
    Ikonomidis I, Papadavid E, Makavos G, et al. · Circ Cardiovasc Imaging · 2017 · Derived
    PubMed: PMID 28899951 · NCT02144857 · Psoriasis
  4. A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale.
    Walker SL, Sales AM, Butlin CR, et al. · PLoS Negl Trop Dis · 2017 · Background
    PubMed: PMID 28671966 · NCT04822909
  5. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
    Schafer PH, Truzzi F, Parton A, et al. · Cell Signal · 2017 · Background
    PubMed: PMID 26806620 · NCT07366268 · Psoriasis
  6. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
    Saba NS, Liu D, Herman SE, et al. · Blood · 2017 · Background
    PubMed: PMID 27127301 · NCT03529955 · Dermatomyositis
  7. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C, Ramming A, Bergmann C, et al. · Ann Rheum Dis · 2017 · Background
    PubMed: PMID 28209630 · NCT03529955 · Dermatomyositis
  8. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M, Myerson GE, Fleischmann RM, et al. · J Rheumatol · 2017 · Background
    PubMed: PMID 27422893 · NCT01212757 (PALACE2) · Psoriasis
  9. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Crowley J, Thaçi D, Joly P, et al. · J Am Acad Dermatol · 2017 · Background
    PubMed: PMID 28416342 · NCT04822909

2016 (6 papers)

  1. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. · J Rheumatol · 2016 · Trial result
    PubMed: PMID 25593233 · NCT01172938 (PALACE-1) · Psoriasis
  2. Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo.
    Vaccaro M, Cannavò SP, Imbesi S, et al. · Int J Dermatol · 2016 · Background
    PubMed: PMID 25427848 · NCT02684123 · Alopecia Areata
  3. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C, Cather J, Gooderham M, et al. · Br J Dermatol · 2016 · Background
    PubMed: PMID 26357944 · NCT07366268 · Psoriasis
  4. Treatment of erosive oral lichen planus with methotrexate.
    Lajevardi V, Ghodsi SZ, Hallaji Z, et al. · J Dtsch Dermatol Ges · 2016 · Background
    PubMed: PMID 26972194 · NCT06260904 · Lichen Planus
  5. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
    Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25904741 · NCT07352566 · Psoriasis
  6. Suppression of Hyperactive Immune Responses Protects against Nitrogen Mustard Injury.
    Au L, Meisch JP, Das LM, et al. · J Invest Dermatol · 2016 · Background
    PubMed: PMID 26288355 · NCT03442088

2015 (7 papers)

  1. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
    Hatemi G, Melikoglu M, Tunc R, et al. · N Engl J Med · 2015 · Derived
    PubMed: PMID 25875256 · NCT00866359 · Behcet Syndrome
  2. Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
    Genovese MC, Jarosova K, Cieślak D, et al. · Arthritis Rheumatol · 2015 · Derived
    PubMed: PMID 25779750 · NCT01285310 · Arthritis, Rheumatoid
  3. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
    Schafer PH, Parton A, Capone L, et al. · Cell Signal · 2015 · Background
    PubMed: PMID 24882690 · NCT07366268 · Psoriasis
  4. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
    Papp K, Reich K, Leonardi CL, et al. · J Am Acad Dermatol · 2015 · Background
    PubMed: PMID 26089047 · NCT07366268 · Psoriasis
  5. The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.
    Liu Y, Zhou S, Wan Y, et al. · Br J Clin Pharmacol · 2015 · Background
    PubMed: PMID 24962564 · NCT01561963
  6. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis.
    Gorouhi F, Davari P, Fazel N, et al. · ScientificWorldJournal · 2015 · Background
    PubMed: PMID 24672362 · NCT06260904 · Lichen Planus
  7. Chronic Psoriatic Skin Inflammation Leads to Increased Monocyte Adhesion and Aggregation.
    Golden JB, Groft SG, Squeri MV, et al. · J Immunol · 2015 · Background
    PubMed: PMID 26223654 · NCT03442088

2014 (6 papers)

  1. Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.
    Strand V, Schett G, Hu C, et al. · J Rheumatol · 2014 · Trial result
    PubMed: PMID 23588944 · NCT00456092 · Arthritis, Psoriatic
  2. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB, Matheson RT, Menter A, et al. · J Drugs Dermatol · 2014 · Trial result
    PubMed: PMID 23986162 · NCT00521339 · Psoriasis
  3. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. · Ann Rheum Dis · 2014 · Derived
    PubMed: PMID 24595547 · NCT01172938 (PALACE-1) · Psoriasis
  4. Methotrexate for treatment of lichen planus: old drug, new indication.
    Kanwar AJ, De D · J Eur Acad Dermatol Venereol · 2014 · Background
    PubMed: PMID 22827806 · NCT06260904 · Lichen Planus
  5. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.
    Fiskus W, Saba N, Shen M, et al. · Cancer Res · 2014 · Background
    PubMed: PMID 24599128 · NCT03529955 · Dermatomyositis
  6. Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages.
    Brunner PM, Koszik F, Reininger B, et al. · J Allergy Clin Immunol · 2014 · Background
    PubMed: PMID 23890755 · NCT03442088

2013 (17 papers)

  1. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
    Strand V, Fiorentino D, Hu C, et al. · Health Qual Life Outcomes · 2013 · Trial result
    PubMed: PMID 23663752 · NCT00773734 · Psoriasis
  2. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
    Pathan E, Abraham S, Van Rossen E, et al. · Ann Rheum Dis · 2013 · Trial result
    PubMed: PMID 22984171 · NCT00944658 (START) · Spondylitis, Ankylosing
  3. An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series.
    Paul J, Foss CE, Hirano SA, et al. · J Am Acad Dermatol · 2013 · Derived
    PubMed: PMID 22910104 · NCT01041625 · Lichen Planus
  4. Monocyte heterogeneity in human cardiovascular disease.
    Zawada AM, Rogacev KS, Schirmer SH, et al. · Immunobiology · 2013 · Background
    PubMed: PMID 22898391 · NCT03442088
  5. CD14++CD16+ monocytes in patients with acute ischaemic heart failure.
    Wrigley BJ, Shantsila E, Tapp LD, et al. · Eur J Clin Invest · 2013 · Background
    PubMed: PMID 23240665 · NCT03442088
  6. TLR4 expression on monocyte subsets in myocardial infarction.
    Tapp LD, Shantsila E, Wrigley BJ, et al. · J Intern Med · 2013 · Background
    PubMed: PMID 23121518 · NCT03442088
  7. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
    Schett G, Wollenhaupt J, Papp K, et al. · Arthritis Rheum · 2013 · Background
    PubMed: PMID 22806399 · NCT00456092 · Arthritis, Psoriatic
  8. Expansion of CD14+CD16+ monocytes producing TNF-α in complication-free diabetes type 1 juvenile onset patients.
    Myśliwska J, Smardzewski M, Marek-Trzonkowska N, et al. · Cytokine · 2013 · Background
    PubMed: PMID 22484242 · NCT03442088
  9. The transcriptome of human monocyte subsets begins to emerge.
    Martinez FO · J Biol · 2013 · Background
    PubMed: PMID 20067595 · NCT03442088
  10. EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments.
    Leng N, Dawson JA, Thomson JA, et al. · Bioinformatics · 2013 · Background
    PubMed: PMID 23428641 · NCT03529955 · Dermatomyositis
  11. Increased gene expression of Toll-like receptor 4 on peripheral blood mononuclear cells in patients with psoriasis.
    Garcia-Rodriguez S, Arias-Santiago S, Perandrés-López R, et al. · J Eur Acad Dermatol Venereol · 2013 · Background
    PubMed: PMID 23457721 · NCT03442088
  12. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome.
    Funderburg NT, Zidar DA, Shive C, et al. · Blood · 2013 · Background
    PubMed: PMID 23065151 · NCT03442088
  13. Comparison between two generic questionnaires to assess satisfaction with medication in chronic diseases.
    Delestras S, Roustit M, Bedouch P, et al. · PLoS One · 2013 · Background
    PubMed: PMID 23437104 · NCT07366268 · Psoriasis
  14. IL-23: one cytokine in control of autoimmunity.
    Croxford AL, Mair F, Becher B, et al. · Eur J Immunol · 2013 · Background
    PubMed: PMID 22949325 · NCT02684123 · Alopecia Areata
  15. Psoriasis and cardiovascular risk factors: increased serum myeloperoxidase and corresponding immunocellular overexpression by Cd11b(+) CD68(+) macrophages in skin lesions.
    Cao LY, Soler DC, Debanne SM, et al. · Am J Transl Res · 2013 · Background
    PubMed: PMID 24349618 · NCT03442088
  16. Alopecia areata update.
    Alkhalifah A · Dermatol Clin · 2013 · Background
    PubMed: PMID 23159179 · NCT02684123 · Alopecia Areata
  17. Graft-versus-host disease after liver transplantation: a comprehensive literature review.
    Akbulut S, Yilmaz M, Yilmaz S, et al. · World J Gastroenterol · 2013 · Background
    PubMed: PMID 23066319 · NCT03529955 · Dermatomyositis

2012 (9 papers)

  1. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.
    Samrao A, Berry TM, Goreshi R, et al. · Arch Dermatol · 2012 · Derived
    PubMed: PMID 22508772 · NCT01393158 · Dermatitis, Atopic
  2. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction.
    Tapp LD, Shantsila E, Wrigley BJ, et al. · J Thromb Haemost · 2012 · Background
    PubMed: PMID 22212813 · NCT03442088
  3. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P · Biochem Pharmacol · 2012 · Background
    PubMed: PMID 22257911 · NCT06032858 · Psoriasis
  4. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography.
    Rogacev KS, Cremers B, Zawada AM, et al. · J Am Coll Cardiol · 2012 · Background
    PubMed: PMID 22999728 · NCT03442088
  5. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).
    Rider LG, Werth VP, Huber AM, et al. · Arthritis Care Res (Hoboken) · 2012 · Background
    PubMed: PMID 22588740 · NCT03529955 · Dermatomyositis
  6. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K, Cather JC, Rosoph L, et al. · Lancet · 2012 · Background
    PubMed: PMID 22748702 · NCT00773734 · Psoriasis
  7. Comparing the clinical and histological diagnosis of leprosy and leprosy reactions in the INFIR cohort of Indian patients with multibacillary leprosy.
    Lockwood DN, Nicholls P, Smith WC, et al. · PLoS Negl Trop Dis · 2012 · Background
    PubMed: PMID 22745841 · NCT04822909
  8. Clinical practice. Lichen planus.
    Le Cleach L, Chosidow O · N Engl J Med · 2012 · Background
    PubMed: PMID 22356325 · NCT06260904 · Lichen Planus
  9. Hand eczema.
    Coenraads PJ · N Engl J Med · 2012 · Background
    PubMed: PMID 23134383 · NCT03741933 (CHD)

2011 (9 papers)

  1. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset.
    Zawada AM, Rogacev KS, Rotter B, et al. · Blood · 2011 · Background
    PubMed: PMID 21803849 · NCT03442088
  2. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets.
    Wong KL, Tai JJ, Wong WC, et al. · Blood · 2011 · Background
    PubMed: PMID 21653326 · NCT03442088
  3. Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology.
    Shantsila E, Wrigley B, Tapp L, et al. · J Thromb Haemost · 2011 · Background
    PubMed: PMID 21342432 · NCT03442088
  4. Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
    Narla A, Dutt S, McAuley JR, et al. · Blood · 2011 · Background
    PubMed: PMID 21527522 · NCT03529955 · Dermatomyositis
  5. Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema.
    Menné T, Johansen JD, Sommerlund M, et al. · Contact Dermatitis · 2011 · Background
    PubMed: PMID 21658053 · NCT03741933 (CHD)
  6. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.
    Mehta NN, Azfar RS, Shin DB, et al. · Eur Heart J · 2011 · Background
    PubMed: PMID 20037179 · NCT03442088
  7. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome.
    Li B, Dewey CN · BMC Bioinformatics · 2011 · Background
    PubMed: PMID 21816040 · NCT03529955 · Dermatomyositis
  8. Economic burden of comorbidities in patients with psoriasis is substantial.
    Kimball AB, Guérin A, Tsaneva M, et al. · J Eur Acad Dermatol Venereol · 2011 · Background
    PubMed: PMID 20561129 · NCT03442088
  9. Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis.
    Gallego C, Golenbock D, Gomez MA, et al. · Infect Immun · 2011 · Background
    PubMed: PMID 21518783 · NCT03442088

2010 (8 papers)

  1. Nomenclature of monocytes and dendritic cells in blood.
    Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. · Blood · 2010 · Background
    PubMed: PMID 20628149 · NCT03442088
  2. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
    Schafer PH, Parton A, Gandhi AK, et al. · Br J Pharmacol · 2010 · Background
    PubMed: PMID 20050849 · NCT03442088
  3. Comorbidities in psoriasis patients.
    Kim N, Thrash B, Menter A, et al. · Semin Cutan Med Surg · 2010 · Background
    PubMed: PMID 20430302 · NCT03442088
  4. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies.
    Farhi D, Dupin N · Clin Dermatol · 2010 · Background
    PubMed: PMID 20082959 · NCT06260904 · Lichen Planus
  5. Consensus statement on the management of chronic hand eczema.
    English J, Aldridge R, Gawkrodger DJ, et al. · Clin Exp Dermatol · 2010 · Background
    PubMed: PMID 19747339 · NCT03741933 (CHD)
  6. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions.
    Davidovici BB, Sattar N, Prinz J, et al. · J Invest Dermatol · 2010 · Background
    PubMed: PMID 20445552 · NCT03442088
  7. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis.
    Chiu YG, Shao T, Feng C, et al. · Arthritis Res Ther · 2010 · Background
    PubMed: PMID 20102624 · NCT03442088
  8. The expression of TNF-alpha and ICAM-1 in lesions of lichen planus and its implication.
    Chen X, Liu Z, Yue Q, et al. · J Huazhong Univ Sci Technolog Med Sci · 2010 · Background
    PubMed: PMID 18231758 · NCT01041625 · Lichen Planus

2009 (8 papers)

  1. Interventions for erythema nodosum leprosum.
    Van Veen NH, Lockwood DN, van Brakel WH, et al. · Cochrane Database Syst Rev · 2009 · Background
    PubMed: PMID 19588412 · NCT04822909
  2. Classification of leprosy into multibacillary and paucibacillary groups: an analysis.
    Parkash O · FEMS Immunol Med Microbiol · 2009 · Background
    PubMed: PMID 19040664 · NCT04822909
  3. Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients.
    Moniuszko M, Bodzenta-Lukaszyk A, Kowal K, et al. · Clin Immunol · 2009 · Background
    PubMed: PMID 18952503 · NCT03442088
  4. Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights.
    Jung T, Stingl G · J Allergy Clin Immunol · 2009 · Background
    PubMed: PMID 18992925 · NCT00931242 · Dermatitis, Atopic
  5. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
    Harada D, Takada C, Nosaka Y, et al. · Int Immunopharmacol · 2009 · Background
    PubMed: PMID 18854230 · NCT00931242 · Dermatitis, Atopic
  6. The impact of psoriasis on health care costs and patient work loss.
    Fowler JF, Duh MS, Rovba L, et al. · J Am Acad Dermatol · 2009 · Background
    PubMed: PMID 19119095 · NCT03442088
  7. Blood monocytes: development, heterogeneity, and relationship with dendritic cells.
    Auffray C, Sieweke MH, Geissmann F, et al. · Annu Rev Immunol · 2009 · Background
    PubMed: PMID 19132917 · NCT03442088
  8. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets.
    Ancuta P, Liu KY, Misra V, et al. · BMC Genomics · 2009 · Background
    PubMed: PMID 19712453 · NCT03442088

2008 (8 papers)

  1. What are the best outcome measurements for atopic eczema? A systematic review.
    Schmitt J, Langan S, Williams HC, et al. · J Allergy Clin Immunol · 2008 · Background
    PubMed: PMID 17910890 · NCT00931242 · Dermatitis, Atopic
  2. Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial.
    Menter A · Cutis · 2008 · Background
    PubMed: PMID 18154219 · NCT03453190 · Psoriasis
  3. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease.
    Hanai H, Iida T, Takeuchi K, et al. · Am J Gastroenterol · 2008 · Background
    PubMed: PMID 18177452 · NCT03442088
  4. Medical consultations in relation to severity of hand eczema in the general population.
    Hald M, Berg ND, Elberling J, et al. · Br J Dermatol · 2008 · Background
    PubMed: PMID 18241259 · NCT03741933 (CHD)
  5. Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis.
    Haider AS, Lowes MA, Suárez-Fariñas M, et al. · J Immunol · 2008 · Background
    PubMed: PMID 18209089 · NCT02684123 · Alopecia Areata
  6. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.
    Gottlieb AB, Strober B, Krueger JG, et al. · Curr Med Res Opin · 2008 · Background
    PubMed: PMID 18419879 · NCT00931242 · Dermatitis, Atopic
  7. Novel immunological approaches in the treatment of atopic eczema.
    Belloni B, Andres C, Ollert M, et al. · Curr Opin Allergy Clin Immunol · 2008 · Background
    PubMed: PMID 18769195 · NCT00931242 · Dermatitis, Atopic
  8. Economic burden of psoriatic arthritis.
    Ackermann C, Kavanaugh A · Pharmacoeconomics · 2008 · Background
    PubMed: PMID 18198932 · NCT03442088

2007 (3 papers)

  1. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
    Krueger GG, Langley RG, Leonardi C, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 17287478 · NCT03442088
  2. Problems encountered during anti-tumour necrosis factor therapy.
    Desai SB, Furst DE · Best Pract Res Clin Rheumatol · 2007 · Background
    PubMed: PMID 16979537 · NCT03442088
  3. The suppression of delayed-type hypersensitivity by CD8+ regulatory T cells requires interferon-gamma.
    Cone RE, Li X, Sharafieh R, et al. · Immunology · 2007 · Background
    PubMed: PMID 17052246 · NCT00931242 · Dermatitis, Atopic

2006 (6 papers)

  1. The psychosocial burden of psoriasis.
    Kimball AB, Jacobson C, Weiss S, et al. · Am J Clin Dermatol · 2006 · Background
    PubMed: PMID 16343026 · NCT03442088
  2. Clinical and economic burden of psoriasis.
    Hazard E, Cherry SB, Lalla D, et al. · Manag Care Interface · 2006 · Background
    PubMed: PMID 16689023 · NCT03442088
  3. The risk of lymphoma in patients with psoriasis.
    Gelfand JM, Shin DB, Neimann AL, et al. · J Invest Dermatol · 2006 · Background
    PubMed: PMID 16741509 · NCT03442088
  4. Relapse, rebound, and psoriasis adverse events: an advisory group report.
    Carey W, Glazer S, Gottlieb AB, et al. · J Am Acad Dermatol · 2006 · Background
    PubMed: PMID 16488339 · NCT03453190 · Psoriasis
  5. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis.
    Beutner K, Chakrabarty A, Lemke S, et al. · J Drugs Dermatol · 2006 · Background
    PubMed: PMID 16673804 · NCT03453190 · Psoriasis
  6. Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis.
    Benoit S, Toksoy A, Ahlmann M, et al. · Br J Dermatol · 2006 · Background
    PubMed: PMID 16792753 · NCT03442088

2005 (4 papers)

  1. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels.
    Schlitt A, Heine GH, Blankenberg S, et al. · Thromb Haemost · 2005 · Background
    PubMed: PMID 15269840 · NCT03442088
  2. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients.
    Louden BA, Pearce DJ, Lang W, et al. · Dermatol Online J · 2005 · Background
    PubMed: PMID 15530297 · NCT07366268 · Psoriasis
  3. Definitions of measures of effect duration for psoriasis treatments.
    Gordon KB, Feldman SR, Koo JY, et al. · Arch Dermatol · 2005 · Background
    PubMed: PMID 15655149 · NCT03453190 · Psoriasis
  4. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
    Feldman SR, Evans C, Russell MW, et al. · J Dermatolog Treat · 2005 · Background
    PubMed: PMID 15897166 · NCT03442088

2004 (3 papers)

  1. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
    Rosenwald A, Chuang EY, Davis RE, et al. · Blood · 2004 · Background
    PubMed: PMID 15138159 · NCT03529955 · Dermatomyositis
  2. Immune mechanisms leading to atopic dermatitis.
    Novak N, Bieber T, Leung DY, et al. · J Allergy Clin Immunol · 2004 · Background
    PubMed: PMID 14657843 · NCT00931242 · Dermatitis, Atopic
  3. New insights into atopic dermatitis.
    Leung DY, Boguniewicz M, Howell MD, et al. · J Clin Invest · 2004 · Background
    PubMed: PMID 14991059 · NCT00931242 · Dermatitis, Atopic

2003 (2 papers)

  1. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects.
    Sontheimer RD · Dermatol Clin · 2003 · Background
    PubMed: PMID 12170874 · NCT03529955 · Dermatomyositis
  2. Blood monocytes consist of two principal subsets with distinct migratory properties.
    Geissmann F, Jung S, Littman DR, et al. · Immunity · 2003 · Background
    PubMed: PMID 12871640 · NCT03442088

2002 (3 papers)

  1. CD14+CD16+ monocytes in the course of sepsis in neonates and small children: monitoring and functional studies.
    Skrzeczyñska J, Kobylarz K, Hartwich Z, et al. · Scand J Immunol · 2002 · Background
    PubMed: PMID 12028567 · NCT03442088
  2. Biologic therapy for psoriasis: the new therapeutic frontier.
    Singri P, West DP, Gordon KB, et al. · Arch Dermatol · 2002 · Background
    PubMed: PMID 12020229 · NCT03442088
  3. T-cell subpopulations in the development of atopic and contact allergy.
    Girolomoni G, Sebastiani S, Albanesi C, et al. · Curr Opin Immunol · 2002 · Background
    PubMed: PMID 11677098 · NCT00931242 · Dermatitis, Atopic

2001 (2 papers)

  1. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.
    Chaudhari U, Romano P, Mulcahy LD, et al. · Lancet · 2001 · Background
    PubMed: PMID 11410193 · NCT03442088
  2. Effector and regulatory T cells in allergic contact dermatitis.
    Cavani A, Albanesi C, Traidl C, et al. · Trends Immunol · 2001 · Background
    PubMed: PMID 11286716 · NCT00931242 · Dermatitis, Atopic

1999 (1 paper)

  1. Treatment of lichen planus. An evidence-based medicine analysis of efficacy.
    Cribier B, Frances C, Chosidow O, et al. · Arch Dermatol · 1999 · Background
    PubMed: PMID 9875189 · NCT01041625 · Lichen Planus

1998 (1 paper)

  1. IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.
    Partida-Sanchez S, Favila-Castillo L, Pedraza-Sanchez S, et al. · Int Arch Allergy Immunol · 1998 · Background
    PubMed: PMID 9623511 · NCT04822909

1997 (2 papers)

  1. Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation.
    Ziegler-Heitbrock HW · Immunol Today · 1997 · Background
    PubMed: PMID 8854561 · NCT03442088
  2. Cytokine production precedes the expansion of CD14+CD16+ monocytes in human sepsis: a case report of a patient with self-induced septicemia.
    Blumenstein M, Boekstegers P, Fraunberger P, et al. · Shock · 1997 · Background
    PubMed: PMID 9249916 · NCT03442088

1994 (1 paper)

  1. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.
    Finlay AY, Khan GK · Clin Exp Dermatol · 1994 · Background
    PubMed: PMID 8033378 · NCT03529955 · Dermatomyositis

1993 (1 paper)

  1. The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients.
    Fingerle G, Pforte A, Passlick B, et al. · Blood · 1993 · Background
    PubMed: PMID 7693040 · NCT03442088

1992 (2 papers)

  1. A prospective study of findings and management in 214 patients with oral lichen planus.
    Silverman S, Gorsky M, Lozada-Nur F, et al. · Oral Surg Oral Med Oral Pathol · 1992 · Background
    PubMed: PMID 1812447 · NCT01041625 · Lichen Planus
  2. Lichen planus.
    Boyd AS, Neldner KH · J Am Acad Dermatol · 1992 · Background
    PubMed: PMID 1791218 · NCT01041625 · Lichen Planus

1978 (1 paper)

  1. Severe psoriasis--oral therapy with a new retinoid.
    Fredriksson T, Pettersson U · Dermatologica · 1978 · Background
    PubMed: PMID 357213 · NCT03453190 · Psoriasis

1966 (1 paper)

  1. Classification of leprosy according to immunity. A five-group system.
    Ridley DS, Jopling WH · Int J Lepr Other Mycobact Dis · 1966 · Background
    PubMed: PMID 5950347 · NCT04822909

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Fri, 17 Jul 2026 03:58:30 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).